Table 2.
Therapeutic efficiency of available treatment options in SIR.
| Treatment Option | DS | RMS | Type A IR |
|---|---|---|---|
| Nutrition: | |||
| Frequent/continuous feeding | Prevents fasting hypoglycaemia | Prevents fasting hypoglycaemia | |
| Avoidance of high carbohydrate diet | Useful | Useful | |
| Insulin sensitizer | No effect | Early usage recommended. Improvement of hyperglycaemia | Early usage recommended. Improvement of hyperglycaemia |
| High dose insulin | No effect | Improvement of hyperglycaemia, catabolic state, weight loss and microvascular complications [14] | Improvement of hyperglycaemia, catabolic state and microvascular complications [14] |
| Metreleptin | No assessment available | Improvement of HbA1c [18] | No study with type A IR patients available. |
| Mecasermin (rhIGF-I) | See Table 3 | See Table 3 | See Table 3 |